Experimental Drugs for Neuropathic Pain

Sałat, Kinga; Gryzło, Beata; Kulig, Katarzyna

doi:10.2174/1570159x16666180510151241

Cited by 23 publications

(18 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also correlated with a wide range of other symptoms and clinical signs linked to sensory abnormalities (Percie du Sert & Rice, 2014). In the general population, the estimated prevalence of NPP ranges from 1.5% to 6.9%, and is largely related to middle age (50–64 years), manual occupations and living in rural areas (Salat, Gryzlo, & Kulig, 2018). Available treatments diverge broadly, including complementary alternative medicine and Western medicine, cognitive–behavioural therapy as well as more invasive interventions (Gilron & Dickenson, 2014).…”

Section: Introductionmentioning

confidence: 99%

Analgesic effect of dexmedetomidine in rats after chronic constriction injury by mediating microRNA‐101 expression and the E2F2–TLR4–NF‐κB axis

Zhang

Cui

et al. 2020

Experimental Physiology

View full text Add to dashboard Cite

New Findings What is the central question of this study?Dexmedetomidine has a capacity for sedation, anti‐anxiety and analgesia with minimal suppression of respiratory function; what is its role in neuropathic pain and what is the involvement of miRNAs? What is the main finding and its importance?Dexmedetomidine attenuates inflammation and apoptosis and the stimulation of TLR4–NF‐κB signalling in rat spinal cord via miR‐101 overexpression and E2F2 downregulation. Abstract The significant analgesic effect of dexmedetomidine (Dex) has been underscored in neuropathic pain (NPP), but the underlying mechanism remains unclear. This study explored the functional effect of Dex on microRNA (miR)‐101‐regulated E2 promoter binding factor 2 (E2F2) with the engagement of Toll‐like receptor 4 (TLR4)–nuclear factor‐κB (NF‐κB) signalling. Chronic constriction injury (CCI) was performed to generate an NPP rat model. The expression of miR‐101, E2F2 and TLR4–NF‐κB signalling‐relevant proteins was assessed by RT–quantitative PCR, immunoblotting and immunohistochemistry. Inflammatory factors were detected by enzyme‐linked immunosorbent assay. The results showed that Dex increased mechanical withdrawal threshold and thermal latency to withdraw. The expression of interleukin (IL)‐6, IL‐8 and tumour necrosis factor‐α was increased in CCI rats, but these trends were reversed by Dex. In addition, Dex repressed caspase‐9 expression and apoptotic cell numbers in spinal cord tissues in CCI rats. Moreover, the expression of E2F2 was significantly increased, while miR‐101 was diminished in CCI rats, which was reversed by Dex. Furthermore, miR‐101 inhibitor, E2F2 restoration or administration of a TLR4‐specific agonist weakened the effect of Dex. Together, these results suggest that Dex has the capacity to ameliorate NPP by regulating the miR‐101–E2F2–TLR4–NF‐κB axis in rats subjected to CCI.

show abstract

Section: Introductionmentioning

confidence: 99%

Analgesic effect of dexmedetomidine in rats after chronic constriction injury by mediating microRNA‐101 expression and the E2F2–TLR4–NF‐κB axis

Zhang

Cui

et al. 2020

Experimental Physiology

View full text Add to dashboard Cite

show abstract

“…NP is a chronic, highly disabling condition caused by a lesion or disease of the somatosensory nervous system which affects from 1.5 to 6.9% of individuals aged 50–64 years ( 10 , 11 ).…”

Section: Discussionmentioning

confidence: 99%

Botulinum Neurotoxin for the Treatment of Neuropathic Pain

2020

View full text Add to dashboard Cite

Botulinum neurotoxin is widely used for the treatment of central and peripherical neurological conditions. Initially used to treat strabismus, over the years its use has been expanded also to spasticity and other neurological disorders. This review summarizes the evidence from the published literature regarding its effect on neuropathic pain. Almost all investigations were performed using onabotulinum toxin type A (BoNT/A). Most studies provided positive results, even though toxin formulation, dose, dilution, injection techniques, and sites are heterogeneous across studies. Future larger, high-quality, specifically designed clinical trials are warranted to confirm botulinum neurotoxin efficacy in neuropathic pain.

show abstract

“…Although it is difficult to quantify, many patients with neuropathic pain have not been diagnosed and many with a diagnosis do not receive adequate analgesia. Neuropathic pain is associated with both pain as well as impaired sensation, often at the periphery, and may occur alone or together with other pain syndromes [9]. Pharmacological therapy for neuropathic pain may include antidepressants and anticonvulsants (gabapentin and pregabalin) and treatment sometimes includes behavioral and cognitive interventions as well [10,11].…”

Section: Introductionmentioning

confidence: 99%

Statins and Neuropathic Pain: A Narrative Review

et al. 2020

View full text Add to dashboard Cite

The frequently prescribed drug class of statins have pleiotropic effects and have been implicated in neuropathic pain syndromes. This narrative review examines studies of statin-induced neuropathic pain which to date have been conducted only in animal models. However, the pathophysiology of diabetic neuropathy in humans may shed some light on the etiology of neuropathic pain. Statins have exhibited a paradoxical effect in that statins appear to reduce neuropathic pain in animals but have been associated with neuropathic pain in humans. While there are certain postulated mechanisms offering elucidation as to how statins might be associated with neuropathic pain, there is, as the American Heart Association stated, to date no definitive association between statins and neuropathic pain. Statins are important drugs that reduce cardiovascular risk factors and should be prescribed to appropriate patients with these risk factors but some of this population is also at elevated risk for neuropathic pain from other causes.

show abstract

Experimental Drugs for Neuropathic Pain

Cited by 23 publications

References 98 publications

Analgesic effect of dexmedetomidine in rats after chronic constriction injury by mediating microRNA‐101 expression and the E2F2–TLR4–NF‐κB axis

Analgesic effect of dexmedetomidine in rats after chronic constriction injury by mediating microRNA‐101 expression and the E2F2–TLR4–NF‐κB axis

Botulinum Neurotoxin for the Treatment of Neuropathic Pain

Statins and Neuropathic Pain: A Narrative Review

Contact Info

Product

Resources

About